Researchers find existing drug could treat Sjögren’s disease
Researchers are closer to understanding what drives the autoimmune disorder Sjögren’s disease, thanks to new discoveries about the role of calcium signalling, regulatory T cells, and interferon.
The study, led by scientists at NYU College of Dentistry and NYU Grossman School of Medicine, was published in Science Translational Medicine.
It finds that impaired regulatory T cells are a critical contributing factor to Sjögren’s disease in both mice and humans, and identifies an existing rheumatology drug as a promising therapy for the disease.
In Sjögren’s disease, the immune system attacks the glands that produce saliva and tears, resulting in dry mouth and eyes. It can also affect other parts of the body, with some patients experiencing fatigue, joint and muscle pain, rashes, and lung inflammation.
The hallmarks of Sjögren’s disease are autoantibodies in the blood and lymphocytes in the salivary glands.
“Sjögren’s disease is an inflammation-driven disease,” said Stefan Feske, the Jeffrey Bergstein Professor of Medicine in the Department of Pathology at NYU Grossman School of Medicine. “There are therapies for Sjögren’s that deplete B cells with antibodies, but they showed mixed results in clinical trials.”
Loss of calcium signalling
Feske and Rodrigo Lacruz, Professor of Molecular Pathobiology at NYU College of Dentistry, undertook two studies on salivary gland cells and immune cells, and focused on cells lacking the Stim1 and Stim2 genes, which interrupt the signalling of calcium, important for saliva production.
In the first study, they found that mice without the Stim1 and Stim2 genes in salivary gland cells had lower saliva production. However, they did not have salivary gland inflammation or increased levels of autoantibodies, suggesting that the loss of calcium signalling in salivary gland cells might actually suppress inflammatory responses.
“We found that a specialised calcium channel activated by STIM1 and STIM2 proteins, the ORAI1 channel, is essential for driving saliva secretion, which is an important discovery. Lack of calcium signals not only impairs function, it may also decrease the effect of inflammatory molecules that have been associated with Sjögren’s disease,” said Lacruz.
The role of Interferon gamma
In the second study, the researchers again studied mice that were lacking Stim1 and Stim2 genes but focused on regulatory T cells instead of salivary gland cells. The dysfunction in regulatory T cells resulted in severe inflammation in the mice that aligned with the classification criteria for Sjögren’s disease: dry eyes, dry mouth, autoantibodies, and lymphocytes in the salivary glands.
“It came down to a defect in regulatory T cells and an overactivation of the cells that produce an inflammatory cytokine called interferon gamma,” said Feske. “Interferon gamma was absolutely critical for causing dysfunction of salivary glands in our mouse model.”
Baricitinib is a Janus kinase (JAK) inhibitor that reduces inflammation by suppressing signals downstream of the interferon receptor. It is currently used to treat rheumatoid arthritis, alopecia, and more recently, hospitalised Covid-19 patients.
When the researchers gave the mice baricitinib, it suppressed salivary gland dysfunction and inflammation.
“Not only did we dissect the underlying cause for Sjögren’s disease in our mouse model, but we correlated these findings to the disease’s classification criteria and genetic signatures in humans,” said Feske. “Moreover, I think using baricitinib has great promise in the treatment of Sjögren’s disease going forward.”
Diana Spencer, Senior Digital Content Editor, DDW
